regulation Archives -

Using ODM standard in CRF design

ODM standard for CRF design

https://pharmaphorum.com/partner-content/odm-standard-for-crf-design/

P-385 Medical Devices 1200 x 675 - PharmaPhorum

Medical Devices and IVD Conference

Nikisha Galoria digital health, MDR, medical devices, patient centricity, regulation 0 Comment

SAE Media Group’s Inaugural Conference… Medical Devices and IVD 2022 14 – 15 November 2022 London, UK http://www.medicaldevices-ivd.com

Medical Devices and IVD Conference

https://pharmaphorum.com/events/medical-devices-and-ivd-conference/

Market Access/ Partner content/ Press releases

Data-driven policy and market access firm Avalere joins Fishawack Health

Fishawack Marketing health economics outcomes research, market access, policy, pricing, regulation 0 Comment

June 7, 2022, Washington DC – Fishawack Health (FH) announces the acquisition of leading healthcare consulting and advisory

Data-driven policy and market access firm Avalere joins Fishawack Health

https://pharmaphorum.com/partner-content/data-driven-policy-and-market-access-firm-avalere-joins-fishawack-health/

Market Access/ News/ News

New bill moves to tighten accelerated approval regulation in US

Eloise McLennan fda, FDA approval, healthcare, patients, regulation 0 Comment

US House Energy & Commerce Committee Chair Frank Pallone (D-NJ) has introduced a new bill to enhance the

New bill moves to tighten accelerated approval regulation in US

https://pharmaphorum.com/news/new-bill-moves-to-tighten-accelerated-approval-regulation-in-us/

Market Access/ News/ News

Japan approves Pfizer COVID vaccine for children aged 5 to 11

Eloise McLennan BioNTech, COVID-19, Pfizer, pharma, regulation, vaccine 0 Comment

Japan’s health ministry has authorised the use of Pfizer and BioNTech COVID-19 vaccine in children aged between five

Japan approves Pfizer COVID vaccine for children aged 5 to 11

https://pharmaphorum.com/news/japan-approves-pfizer-covid-vaccine-for-children-aged-5-to-11/

News/ News/ Oncology

Scotland backs AstraZeneca drug as first-line treatment for NSCLC

Eloise McLennan AstraZeneca, cancer, pharma, regulation 0 Comment

Scotland has approved AstraZeneca’s Tagrisso (osimertinib) as a monotherapy for the for the first-line treatment of adult patients

Scotland backs AstraZeneca drug as first-line treatment for NSCLC

https://pharmaphorum.com/news/scotland-backs-astrazeneca-drug-first-line-treatment-nsclc/

Market Access/ News/ News

Two new drugs added to WHO list of COVID-19 therapies

Joy Persaud COVID-19, Eli Lilly, GlaxoSmithKline, market access, pharma, regulation, WHO 0 Comment

A World Health Organization (WHO) panel has given the green light to two new drugs to treat COVID-19.

Two new drugs added to WHO list of COVID-19 therapies

https://pharmaphorum.com/news/two-new-drugs-added-to-who-list-of-covid-19-therapies/

Views and analysis

Innovation and access: Improving Europe’s pharmaceutical regulatory framework

Amanda Barrell EFPIA, Innovation, market access, regulation, regulatory approval 0 Comment

EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis. Only a regulatory

Innovation and access: Improving Europe’s pharmaceutical regulatory framework

https://pharmaphorum.com/views-and-analysis/innovation-and-access-improving-europes-pharmaceutical-regulatory-framework/

Market Access/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Nine for 2022: International issues that are compelling, new or changed in 2022

mike.hammerton@pharmaphorum.com COVID vaccine, COVID-19, R&D, regulation, vaccine 0 Comment

The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan,

Nine for 2022: International issues that are compelling, new or changed in 2022

https://pharmaphorum.com/r-d/international-issues-compelling-new-changed-2022/

Trending

regulation

Login